These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15769927)

  • 1. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.
    Talwalkar SC; Grennan DM; Gray J; Johnson P; Hayton MJ
    Ann Rheum Dis; 2005 Apr; 64(4):650-1. PubMed ID: 15769927
    [No Abstract]   [Full Text] [Related]  

  • 2. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications?
    Kawakami K; Ikari K; Kawamura K; Tsukahara S; Iwamoto T; Yano K; Sakuma Y; Tokita A; Momohara S
    Rheumatology (Oxford); 2010 Feb; 49(2):341-7. PubMed ID: 19965973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.
    Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D
    Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348
    [No Abstract]   [Full Text] [Related]  

  • 4. Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data.
    Jain A; Maini R; Nanchahal J
    Ann Rheum Dis; 2004 May; 63(5):602-3. PubMed ID: 15082498
    [No Abstract]   [Full Text] [Related]  

  • 5. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
    Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
    Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
    [No Abstract]   [Full Text] [Related]  

  • 8. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections?
    Pappas DA; Giles JT
    Curr Opin Rheumatol; 2008 Jul; 20(4):450-6. PubMed ID: 18525360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents.
    Goupille P; Pham T; Sibilia J; Mariette X
    Semin Arthritis Rheum; 2007 Dec; 37(3):202-3; author reply 203. PubMed ID: 17570470
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour necrosis factor alpha blockade and the risk of vasculitis.
    De Bandt M; Saint-Marcoux B
    Ann Rheum Dis; 2006 Nov; 65(11):1534-5. PubMed ID: 17038458
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 16. Granulomatous lung disease occurring during etanercept treatment.
    Phillips K; Weinblatt M
    Arthritis Rheum; 2005 Aug; 53(4):618-20. PubMed ID: 16082636
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate and post operative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery--a ten year follow-up.
    Sreekumar R; Gray J; Kay P; Grennan DM
    Acta Orthop Belg; 2011 Dec; 77(6):823-6. PubMed ID: 22308630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 20. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
    Silburn S; McIvor E; McEntegart A; Wilson H
    Ann Rheum Dis; 2008 Apr; 67(4):575-6. PubMed ID: 18349168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.